MedTrace Logo

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-02-23

No results posted yet for this study

Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Conditions

  • Relapsed or Refractory Lymphoma

Interventions

DRUG

HMPL-523

700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

DRUG

Rabeprazole

40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-13
Primary Completion
2022-09-22
Completion
2022-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05571787 on ClinicalTrials.gov